SAN FRANCISCO, CA–(Marketwired – June 02, 2016) – Cancer patients often receive multiple rounds of chemotherapy, with new drugs incorporated into treatment programs as tumors develop resistance. OncoSec Medical Incorporated’s (NASDAQ: ONCS) Punit Dhillon describes how his company is challenging that paradigm with a proprietary platform that delivers therapeutic agents directly to the tumor, while also laying a foundation for expanded use of combination immunotherapies at the forefront of cancer treatment.
The Life Sciences Report:
Can you give us a brief overview of OncoSec Medical Incorporated?
Punit Dhillon: OncoSec is a biotechnology company focused on developing new technologies that harness the body’s immune system to fight cancer. Our core investigational immunotherapy platform, ImmunoPulse™, is designed to deliver DNA-based therapeutics directly into tumors and reverse the immuno-suppressive tumor microenvironment. We have an experienced leadership team, including senior management and scientists who have extensive backgrounds in drug development, cancer immunology and partnering. The company is publicly traded on NASDAQ.
Continue reading this interview: OncoSec Delivers Cancer Therapy Straight to the Tumor
About Streetwise Reports — The Life Sciences Report
Investors rely on The Life Sciences Report
to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
DISCLOSURE:
OncoSec Medical Incorporated paid Streetwise Reports to produce and distribute this interview. Punit Dhillon had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Dhillon and not of Streetwise Reports or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.
Please see Streetwise Reports’ terms of use and full legal disclaimer.
Jim Patrick
Email contact